PDT Partners LLC Boosts Stock Position in Theravance Biopharma, Inc. $TBPH

Key Points

• PDT Partners LLC significantly increased its holdings in Theravance Biopharma, Inc. by 135.1%, acquiring an additional 50,901 shares to hold a total of 88,577 shares, valued at approximately $791,000.
• Several institutional investors, including Vanguard Group Inc. and Dimensional Fund Advisors LP, also raised their stakes in Theravance Biopharma, contributing to the overall 99.10% institutional ownership of the company.
• Analysts have upgraded Theravance Biopharma's stock to a strong-buy rating, with an average price target of $21.33, indicating positive sentiment towards the company's future performance.

PDT Partners LLC grew its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 135.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,577 shares of the biopharmaceutical company's stock after purchasing an additional 50,901 shares during the quarter. PDT Partners LLC owned approximately 0.18% of Theravance Biopharma worth $791,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in Theravance Biopharma by 27.6% in the fourth quarter. Wells Fargo & Company MN now owns 21,704 shares of the biopharmaceutical company's stock worth $204,000 after acquiring an additional 4,695 shares in the last quarter. Barclays PLC grew its stake in Theravance Biopharma by 14.0% during the 4th quarter. Barclays PLC now owns 74,790 shares of the biopharmaceutical company's stock valued at $704,000 after purchasing an additional 9,210 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after purchasing an additional 95,304 shares during the period. Tower Research Capital LLC TRC increased its stake in Theravance Biopharma by 142.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,670 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 7,452 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Theravance Biopharma by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company's stock valued at $610,000 after purchasing an additional 9,315 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Trading Down 0.2%

NASDAQ:TBPH traded down $0.03 during midday trading on Monday, hitting $13.92. 387,254 shares of the company traded hands, compared to its average volume of 288,391. Theravance Biopharma, Inc. has a 12-month low of $7.88 and a 12-month high of $14.55. The firm's fifty day moving average is $12.12 and its 200-day moving average is $10.45. The firm has a market capitalization of $701.01 million, a P/E ratio of 58.00 and a beta of 0.04.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president owned 326,918 shares of the company's stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is owned by insiders.

Analysts Set New Price Targets

TBPH has been the topic of several research analyst reports. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. BTIG Research increased their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Finally, Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Strong Buy" and an average target price of $21.33.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.